Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Exagen Inc. - Common Stock (NQ:XGN)

7.330 +0.140 (+1.95%)
Streaming Delayed Price Updated: 9:30 AM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exagen Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
From Exagen Inc.
Via GlobeNewswire
Top movers in Thursday's pre-market session
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Exagen Inc. Prices Public Offering of Common Stock
From Exagen Inc.
Via GlobeNewswire
Earnings Scheduled For May 5, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Exagen Inc. Announces Proposed Public Offering of Common Stock
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
From Exagen Inc.
Via GlobeNewswire
Earnings Scheduled For March 11, 2025
Via Benzinga
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in Upcoming Investor Conferences
From Exagen Inc.
Via GlobeNewswire
Tuesday's session: top gainers and losers
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care 
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease 
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Third Quarter 2024 Results
From Exagen Inc.
Via GlobeNewswire
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
From Exagen Inc.
Via GlobeNewswire
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
From Exagen Inc.
Via GlobeNewswire
Market Mayhem Winners: What Stocks Are Up Today?
What stocks are up today? It’s a natural question following the implosion of the global markets and the answer might surprise you. 
Via InvestorPlace
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024
XGN stock results show that Exagen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Exagen Inc.
Via GlobeNewswire
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
From Exagen Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.